College of Pharmacy, Dongguk University-Seoul, Dongguk-ro-32, Ilsan-Donggu, Goyang, Korea.
J Nanobiotechnology. 2020 Jul 25;18(1):104. doi: 10.1186/s12951-020-00662-x.
This study aimed to develop a ternary nanocomposite system of organoclay, glycol-chitosan, and EudragitS100 as an effective colon targeted drug delivery carrier to enhance the oral absorption of insulin. A nanocomplex of insulin and aminoclay was prepared via spontaneous co-assembly, which was then coated with glycol-chitosan and Eudragit S100 (EGAC-Ins). The double coated nanocomplex, EGAC-Ins demonstrated a high entrapment efficiency of greater than 90% and a pH-dependent drug release. The conformational stability of insulin entrapped in EGAC-Ins was effectively maintained in the presence of proteolytic enzymes. When compared to a free insulin solution, EGAC-Ins enhanced drug permeability by approximately sevenfold in Caco-2 cells and enhanced colonic drug absorption in rats. Accordingly, oral EGAC-Ins significantly reduced blood glucose levels in diabetic rats while the hypoglycemic effect of an oral insulin solution was negligible. In conclusion, EGAC-Ins should be a promising colonic delivery system for improving the oral absorption of insulin.
本研究旨在开发一种有机粘土、乙二醇壳聚糖和 EudragitS100 的三元纳米复合体系,作为一种有效的结肠靶向药物传递载体,以增强胰岛素的口服吸收。通过自发共组装制备了胰岛素和氨基粘土的纳米复合物,然后用乙二醇壳聚糖和 Eudragit S100(EGAC-Ins)进行包衣。双层包衣纳米复合物 EGAC-Ins 的包封效率大于 90%,且具有 pH 依赖性药物释放。在存在蛋白水解酶的情况下,EGAC-Ins 中包封的胰岛素的构象稳定性得到有效维持。与游离胰岛素溶液相比,EGAC-Ins 可使 Caco-2 细胞中药物渗透性提高约 7 倍,并增强大鼠结肠的药物吸收。因此,口服 EGAC-Ins 可显著降低糖尿病大鼠的血糖水平,而口服胰岛素溶液的降血糖作用则可以忽略不计。总之,EGAC-Ins 有望成为改善胰岛素口服吸收的结肠递药系统。